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ABSTRACT  
 
Background and Aims: Following induction/maintenance treatment in the UNITI/IM-UNITI 
studies of ustekinumab for Crohn’s disease, patients entered a long-term extension for up to 5 
years from induction. Efficacy through 152 and safety through 156 weeks are reported. 
 
Methods: At IM-UNITI Week 44, 567 ustekinumab-treated patients entered the long-term 
extension and continued to receive blinded subcutaneous ustekinumab on their assigned dose 
interval, without any subsequent dose adjustment. Placebo-treated patients discontinued after 
study unblinding (after IM-UNITI Week 44 analyses). Efficacy data in the LTE were collected 
every 12 weeks (q12w) prior to unblinding and then at q12w/q8w dosing visits.  
 
Results: Through Week 156, 29.6% of ustekinumab-treated patients discontinued. In an intent-
to-treat analysis of randomized patients from IM-UNITI Week 0-152, 38.0% of ustekinumab 
induction responders receiving drug q12w and 43.0% q8w were in remission at Week 152. 
Among patients entering the long-term extension in their original randomized groups, 61.9% of 
q12w and 69.5% of q8w patients were in remission at Week 152. Across all ustekinumab-treated 
patients (randomized and non-randomized) entering the long-term extension, remission rates at 
Week 152 were 56.3% and 55.1% for q12w and q8w, respectively.   
 
Safety events (per hundred patient-years) were similar among all ustekinumab-treated patients 
entering the long-term extension and placebo (overall adverse events 389.70 vs 444.17; serious 
adverse events, 18.97 vs 19.54; serious infections, 4.21 vs 3.97). Rates of antibodies to 
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ustekinumab through Week 156 remained low, 4.6% in all randomized ustekinumab-treated 
patients; lowest among patients in the original randomized q8w group (2/82, 2.4%). 
 
Conclusion: Continued treatment with subcutaneous ustekinumab maintained clinical response 
and remission through 3 years in a majority of patients who responded to induction therapy and 
was well-tolerated. ClinicalTrials.gov number NCT01369355. 
 
Keywords: ustekinumab, Crohn’s disease, long-term
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INTRODUCTION 
 
Crohn’s disease (CD) is a chronic inflammatory bowel disease that usually requires long-term 
medical therapy to control symptoms and prevent disease-related complications.
1
 Ustekinumab, a 
fully human monoclonal antibody to interleukin-12/23p40, is approved for the treatment of 
moderate-to-severe active CD. The efficacy and safety of ustekinumab in CD through 1 year has 
been previously established in the UNITI-1 and UNITI-2 (8 weeks) and IM-UNITI (44 weeks) 
studies.
2
  
 
However, given the need for continued treatment in CD, the durability of response to biologic 
therapy is a critical clinical question of these agents for maintaining response and remission. 
Although multiple factors can result in discontinuation of therapy, including patient and or 
provider wishes, development of adverse events or biological resistance to a drug’s mechanism 
of action, the development of antidrug antibodies (ADAs) to biologics is an important factor 
because they both could diminish drug efficacy and increase the risk of infusion or injection 
reactions.
3
 Over the past two decades, multiple publications have documented the importance of 
sensitization in patients treated with tumor necrosis factor (TNF) antagonists, as well as other 
biologics.
4
 The development of ADAs to infliximab is associated with an increased risk of 
infusion reactions and a reduced duration of response to treatment.
5
 This problem also occurs 
with the fully humanized antibody, adalimumab. A review paper that included 23 adalimumab 
studies identified that the prevalence of ADAs was 0.3 to 38% and that their development was 
associated with reduced efficacy, loss of response, and high rate of secondary treatment failure.
6
 
In studies of certolizumab pegol ADAs were reported in 3.3-25% of patients.
6
 In a recent 
analysis anti-vedolizumab antibodies were detected in 17% of patients during induction therapy 
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and 3% of patients during maintenance therapy, although no correlation was observed between  
clinical outcomes and the development of ADAs.
7
 Additionally, it was noted that the low 
prevalence and transient nature of ADAs in patients who discontinued vedolizumab treatment 
may indicate that immunogenicity was not the key factor in treatment failure.
8
    
 
The previous report of the IM-UNITI long-term extension (LTE) data through 2 years showed 
that subcutaneous ustekinumab maintained clinical response and remission through Week 92 and 
was well-tolerated.
9
 The efficacy results for the IM-UNITI study through Week 152 and safety 
results through Week 156 presented here provide additional data on the long-term treatment 
effects of ustekinumab highlighting the sustainability of the clinical effects of ustekinumab 
through 3 years with continued low rates of immunogenicity. 
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MATERIALS AND METHODS 
 
Study Design and Endpoints 
 
The ustekinumab program included 2 randomized, double blind, placebo-controlled 8-week 
induction studies (UNITI-1 and UNITI-2) as well as a maintenance phase through Week 44 (IM-
UNITI). Detailed study design and efficacy results from the induction and maintenance study,
2
 
as well as results from the LTE through Week 96 have been previously published.
9
 
 
Briefly, all patients who completed treatment through Week 44 of IM-UNITI were eligible to 
enter the LTE. Unblinding occurred after the Week 44 analyses (August 2015) and patients 
continued the same treatment they were receiving at Week 44 (subcutaneous [SC] placebo, 
ustekinumab 90 mg every 8 weeks [q8w] or every 12 weeks [q12w]); no dose adjustment 
occurred in the LTE. Placebo-treated patients were discontinued after unblinding. Efficacy 
assessments in the LTE were conducted q12w until unblinding and then q8w or q12w at dosing 
visits. As in the previous studies,
2, 9
 clinical remission was defined as a Crohn’s Disease Activity 
index (CDAI) score of <150 points and clinical response was defined as a reduction from Week 
0 of UNITI‐ 1 or UNITI‐ 2 in the CDAI score of ≥100 points (or if a CDAI score of <150 was 
attained). Corticosteroid‐ free remission was defined as a CDAI score of <150 points without 
receiving corticosteroids at Week 152. 
 
The populations included in the analyses were the same as those analyzed and detailed 
previously in the Week 96 manuscript
9
 and are briefly described here. The randomized patient 
population included only those patients randomized in the maintenance trial who continued into 
the LTE (ustekinumab 90 mg q12w- patients randomized to q12w dosing in maintenance with no 
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dose adjustment; ustekinumab 90 mg q8w-patients randomized to q8w dosing in maintenance 
with no dose adjustment; dose adjusters-all patients who dose adjusted between Weeks 8 and 32 
during maintenance [Placebo→ ustekinumab q8w, ustekinumab q12w→q8w, ustekinumab 
q8w→q8w]). Dose adjustment was not permitted in the LTE. The all patient population included 
all patients who entered the LTE (randomized and non-randomized patients) who received 
ustekinumab q8w or every q12w (Figure 1).  
 
The incidence of antibodies to ustekinumab was evaluated, using a validated, drug-tolerant 
electrochemiluminescence immunoassay (ADA detected in up to 100 µg/mL of ustekinumab 
without interference), for all treated patients who entered the LTE and received at least 1 
administration of ustekinumab, either in the induction studies (UNITI-1 or UNITI-2) or IM-
UNITI (through Week 44), and had appropriate samples for detection of antibodies to 
ustekinumab (i.e., patients with at least 1 sample obtained after their first dose of ustekinumab). 
The relationships between antibody to ustekinumab status through Week 152 and clinical 
response and remission status, as well as injection-site reactions through Week 152 were 
explored. 
Statistical Analysis 
Because placebo patients discontinued the study after treatment assignments were unblinded to 
investigative sites (after the last patient completed Week 44 and database lock and subsequent 
analyses were completed), direct comparisons and/or statistical comparisons of efficacy results 
between placebo and ustekinumab treatment groups throughout the extension were not 
considered appropriate for efficacy endpoints. Instead, summaries of the data for the 
ustekinumab groups are provided. 
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Demographic and baseline disease characteristics, efficacy, and safety analyses were based on all 
patients treated with at least 1 administration of study agent during the LTE. Descriptive 
statistics (eg, mean, median, standard deviation, interquartile range, minimum, and maximum) 
were used to summarize continuous variables. Counts and percentages were used to summarize 
categorical variables. Kaplan-Meier curves were provided for the time to loss of response 
analysis. 
The analyses conducted evaluated (1) All randomized patients in maintenance, regardless of 
whether they entered the LTE (intent-to-treat analysis of randomized patients from Week 0 of 
IM-UNITI), (2) Patients who entered LTE (randomized patients and all patients), (3) observed 
cases with inclusion only of randomized patients who entered the LTE and who had data at a 
designated visit.  
 
For all efficacy analyses, patients with a CD-related surgery or who discontinued study agent due 
to lack of efficacy or an adverse event indicated to be worsening CD after Week 44 and prior to 
the designated analysis time point were considered not to be in clinical remission/response, 
regardless of their CDAI score. Patients with insufficient data to calculate the CDAI score at the 
designated analysis time point were considered not to be in clinical remission/response (patients 
were excluded for the observed case analysis). Other dichotomous endpoints followed the same 
treatment failure and missing data rules.  
For continuous endpoints, patients meeting these treatment failure rules prior to the designated 
analysis time point had their induction baseline value carried forward and if there was 
insufficient data to calculate the variable at the designated analysis time points their last value 
was carried forward.  
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RESULTS 
 
Baseline Characteristics 
Upon completion of Week 44 of IM-UNITI, 567 ustekinumab patients entered into the LTE. Of 
these, 237 patients were from the primary population (induction responders to ustekinumab re-
randomized at Week 0 of maintenance) including 84 patients receiving q12w ustekinumab and 
153 patients receiving q8w ustekinumab, 71 of whom had undergone dose adjustment (Figure 1; 
Supplemental Figure 1). Clinical characteristics for the population of patients enrolled in the 3-
year LTE were the same for those reported in the 2-year LTE.
9
 Among randomized patients, 
median CDAI score at Week 44 was similar in patients in the ustekinumab q8w (70.5) and q12w 
(95.5) groups and higher in dose adjustment group (130.0; Table 1). The proportion of 
randomized patients in clinical remission at Week 44 was lower in the dose adjustment group 
(63.4%) than in the ustekinumab q8w (84.1%) and q12w (77.4%) groups. Clinical characteristics 
were similar for the all patient population (Table 1).  
 
Discontinuation 
Rates of discontinuation of study agent through Week 156 from the original randomized patients 
were 22.0%, 27.4%, and 33.8% in the ustekinumab q8w, q12w, and dose adjuster groups, 
respectively (Table 2). Among all randomized patients who received ustekinumab, the most 
common reasons for discontinuation of study agent were adverse events (AEs), lack of efficacy, 
physician decision, lost to follow-up, and withdraw of consent. In the placebo group 93.4% of 
patients discontinued study agent; 65.6% due to per-protocol study unblinding.  
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Efficacy  
 
Intent-to-treat analysis of randomized patients from Week 0 of maintenance  
 
The proportions of patients in clinical remission from Week 44 to Week 152 in both the 
ustekinumab treatment groups were 53.1% to 43.0% and 48.8% to 38.0% in the q8w and q12w 
groups, respectively (Figure 2A). Similar trends were observed among randomized TNF-naïve 
patients from Week 44 through Week 152 (Figure 2B).  
 
Randomized patients entering long-term extension 
 
Through year 3 of the IM-UNITI LTE, both the ustekinumab q8w and q12w doses performed 
similarly for most clinical measures with a slightly higher percentage of patients in clinical 
remission at Week 152 among patients receiving ustekinumab q8w (69.5%) than patients 
receiving ustekinumab q12w (61.9%) (Table 3). From Week 92 through Week 152, a substantial 
percentage of patients maintained remission in both the UNITI-1 population (70.4% to 59.3%, 
respectively for the ustekinumab q8w group and 59.4% to 43.8%, respectively for the 
ustekinumab q12w group) and UNITI-2 population (80.8% to 73.1%, respectively in the 
ustekinumab q8w group and 76.4% to 74.5%, respectively, in the q12w group). Maintenance of 
remission was more stable among the UNITI-2 populations (Figure 3).   
 
Percentages of patients with steroid-free remission (remission and not receiving corticosteroids) 
at Week 152 were higher in both the ustekinumab 90mg q8w and q12w groups (61.0% and 
54.8%, respectively) compared with those receiving dose adjustment (39.4%; Table 3). In both 
ustekinumab groups, among patients who were receiving corticosteroids at maintenance baseline, 
73.5% were able to eliminate corticosteroid use by Week 152, compared with 52.6% of patients 
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who had dose adjusted (Supplemental Figure 2).  A post-hoc analysis, showed that sustained 
corticosteroid-free remission (at weeks 128, 140, and 152) was achieved by 53.7% (44/82) and 
47.6% (40/84) patients in the ustekinumab 90mg q8w and q12w groups, respectively, compared 
with 32.4% (23/71) of those who dose adjusted. 
 
Patients in the ustekinumab q8w and q12w groups achieved median reductions from CDAI 
maintenance baseline scores of 38.5 and 39.5 points, respectively, compared with a 15.0-point 
decrease in those patients who had a prior dose adjustment (Table 3). Median (C-reactive 
protein) CRP over time was stable and similar in both ustekinumab q8w and q12w groups 
(Supplemental Figure 3).  
 
The difference in the time to loss of response from Weeks 44 to 152 between the ustekinumab 
q8w group and q12w group was statistically significant (log rank test p=0.044, Figure 4). The 
time to loss of response was longer for the q8w group compared with the q12w group. 
 
All treated patients entering long-term extension 
  
At Week 152, 55.1% and 56.3% of patients in the ustekinumab q8w and q12w groups were in 
remission (Figure 5). From Week 92 to Week 152, rates of remission were generally maintained 
in both ustekinumab groups (64.4% to 55.1% in the q8w group and 64.3% to 56.3% in the q12w 
group, respectively).  
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No association was observed between immunomodulator and corticosteroid use at Week 44 and 
long-term remission at Week 152. Patients without prior stricturing disease had higher rates of 
remission at Week 152 in the ustekinumab q8w and q12w groups.  
 
Observed case analysis of randomized patients entering long-term extension 
 
Higher proportions of patients achieved remission at Week 152 in the ustekinumab q8w group 
than in the ustekinumab q12w group (82.6% and 74.3%, respectively; Supplemental Figure 4).  
 
Safety   
All treated patients entering long-term extension 
Week 0-Week 156 
From Week 0 through Week 156, safety events (per hundred patient-years) were similar among 
all ustekinumab-treated patients compared to placebo, including overall adverse events (389.70 
vs 444.17), serious adverse events (18.97 vs 19.54), and serious infections (4.21 vs 3.97), 
respectively, with an average of 141.7 weeks and 1544.8 patients-years of follow-up for all 
ustekinumab-treated patients (Table 4).  
 
Week 44-Week 156 
From Week 44 through Week 156, safety events (per hundred patient-years) were similar among 
all ustekinumab-treated patients compared to placebo, including overall adverse events (325.26 
vs 358.80), serious adverse events (19.40 vs 23.11), and serious infections (4.14 vs 4.62), 
respectively, with an average of 97.4 weeks and 1061.6 patients-years of follow-up for all 
ustekinumab-treated patients (data not shown). 
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Among all patients entering the LTE, 48 patients had one or more serious infections. Serious 
infections occurring in 2 or more ustekinumab-treated patients included: anal abscess (1.4%), 
pneumonia (0.7%), cellulitis (0.4%), gastroenteritis (0.4%), perirectal abscess (0.4%), 
pyelonephritis (0.4%), and sepsis (0.4%). Other serious infections of interest included 
cytomegalovirus colitis and liver abscess in two patients receiving placebo.  
 
Overall, 4 solid and hematologic malignancies were reported which included testicular 
seminoma, adenocarcinoma of small intestine, chronic myeloid leukemia in patients on 
ustekinumab in the study extension and a papillary thyroid cancer in a patient who remained on 
placebo throughout the study. Through 3 years, seven non-melanoma skin cancers were reported, 
of which 5 patients had prior or concomitant exposure to thiopurines. There were 4 basal cell 
carcinomas: 2 reported from Week 96 through Week 156 in patients who received  ustekinumab 
induction and maintenance and as previously reported, 1 patient who received ustekinumab 
induction and maintenance and 1 patient who received placebo induction/ ustekinumab 
maintenance /ustekinumab LTE; and 3 squamous cell carcinomas: 1 reported from Week 96 
through Week 156 in a single patient on placebo induction/ ustekinumab maintenance 
/ustekinumab LTE; and as previously reported, 1 patient on ustekinumab induction/placebo 
maintenance/LTE and 1 patient on placebo only. 
 
One case of tuberculosis was previously reported (deemed unrelated to study drug and 
completely resolved with therapy) in the long-term extension.
9 
No new cases on TB occurred in 
the third year.  
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Six deaths were reported from Week 44 through Week 156. Three were reported from Week 96 
through Week 156; including individual patients with end stage renal disease, acute myocardial 
infarction and septic shock. None of the deaths were deemed related to ustekinumab. 
 
Immunogenicity in the randomized population 
The rates of antibodies to ustekinumab formation (using a sensitive drug-tolerant assay) 
remained low through Week 156 with 4.6% (11/237) of all ustekinumab treated patients testing 
positive for antibodies to ustekinumab at any point during maintenance through Week 156. Rates 
were higher in patients who were initially assigned to placebo, 8.2% (Table 5). Rates were 
lowest among patients who remained on continuous q8w dosing without dose adjustment (2/82, 
2.4%; Table 5). Rates of antibody formation were similar between patients not receiving 
concomitant immunosuppressive at Week 44 (7/157, 4.5%) compared to those on 
immunosuppressives at Week 44 (4/80, 5.0%; Supplemental Table 1). There was no apparent 
relationship across the various randomized groups between antibody status and efficacy 
(Supplemental Table 2). 
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DISCUSSION 
 
IM-UNITI is a 5-year maintenance study designed to evaluate the efficacy and safety of long-
term ustekinumab therapy for CD. Previously published data demonstrated that in ustekinumab 
induction responders, remission and response rates were maintained through the original primary 
endpoint at Week 44
2
 and subsequently through Week 92.
9 
Here, we report that in ustekinumab 
induction responders, remission and response rates were generally maintained in both TNF 
antagonist failure and non-failure populations through Week 152. Consistent with the previously 
reported data, rates of maintenance of remission were more stable among the TNF antagonist 
non-failure population and in patients who had not experienced dose adjustment prior to Week 
44. Non-randomized patients performed similarly to the randomized population. Both q8w and 
q12w week ustekinumab SC dosing regimens were effective and the difference between the 
dosing regimens was not clinically meaningful from Week 92 to Week 152. 
 
The efficacy analyses presented here, all demonstrating substantial maintenance of efficacy 
through 3 years, are comprehensive. They include analysis of patients who entered the LTE (both 
randomized and all patients), observed case analysis with inclusion only of randomized patients 
who entered the LTE who have data at that visit, and analysis of all randomized patients in 
maintenance, regardless of whether they entered the LTE. The latter was performed according to 
the intent-to-treat principle and therefore provides conservative efficacy estimates for the 
randomized population from the beginning of maintenance. Additionally, all patients remained 
on stable dosing without dose adjustment in the LTE. It is notable that 43% of the q8w and 38% 
of the q12w SC ustekinumab groups are in remission at Week 152 using this most stringent 
analysis. The observed case analysis is presented since it is often included in other biologic LTE 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz110/5510474 by U
niversity of Birm
ingham
 user on 17 July 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz110 
 
publications 
10-12
 and demonstrates the range of results depending on the analysis, with 83% of 
the q8w and 74% of the q12w ustekinumab groups in remission at Week 152. 
 
The low immunogenicity rates of ustekinumab may be related to the maintenance of response in 
CD. Formation of ADAs is thought to be one of the most important causes of loss of response to 
anti-TNF agents and development of ADAs to infliximab can lead to an increased risk of 
infusion reaction and reduced duration of response.
5
 In addition, antibody formation may 
accelerate drug clearance due to the formation of immune complexes.
13
 The potential for 
immunogenicity of biologics can be influenced by multiple factors that may be molecule, patient, 
or assay related. The use of the drug-tolerant assay used in this study may remove some of the 
questions around assay-related immunogenicity. Although the precise reason for the low 
immunogenicity profile of ustekinumab is unknown, it may be that the molecule itself and the 
mechanism of action are responsible for the low immunogenic profile.  
 
Cross compound comparison of immunogenicity is challenging, due to differences in 
immunogenicity assays and study design.  However, a recent  systematic review reported the 
highest rates in infliximab and adalimumab, followed by certolizumab pegol, with lower rates 
observed  in ustekinumab and golimumab treated patients.
14
 While rates of ADA formation were 
low in  the pivotal CD and UC studies of vedolizumab, 3.7-4.1%,
15, 16
 a recent study reported 
anti-vedolizumab antibodies were detected in 17% of patients during induction therapy and 3% 
of patients during maintenance therapy, although no correlation was seen with clinical outcomes
7
 
and immunogenicity was not considered a key factor in treatment failure.
8
 Rates of antibodies to 
ustekinumab in the randomized CD Phase 3 program were low; 2.3% through Week 44,
2
 4.2% at 
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Week 96,
9 
and 4.6% through Week 156, and were low either with or without the use of 
concomitant immunomodulators. Antibody positivity was not related to efficacy. 
 
Despite the longer follow-up, the safety data in this manuscript are consistent with the safety 
previously reported in ustekinumab CD studies
2, 9 
and with ustekinumab long-term treatment of 
psoriasis.
17-19
 The overall rates of adverse events and serious adverse events were comparable to 
placebo through Week 156. No new safety signals were identified between Weeks 96 and 156.  
Rates of serious infection and malignancy remained low and use of concomitant therapies did not 
appear to influence the overall safety or efficacy of ustekinumab. While the 3-year data is 
reassuring, limited numbers of patients may not allow detection of rare events.  
 
Limitations to the LTE have been previously discussed.
9
 Additionally, it should be noted that 
since there was no opportunity for patients to dose-escalate in this LTE, proportions of patients 
remaining on ustekinumab maintenance in this study may be lower than what would be seen in 
real-world practice, where such escalation is possible. 
 
In conclusion, SC ustekinumab maintained clinical response and remission through 3 years in a 
substantial proportion of patients, including a unique intent-to-treat population, and in 
particularly those who were naïve to TNF antagonists. Immunogenicity rates remained low, were 
not lower in patients on concomitant immunosuppressives, and antibodies did not seem to affect 
clinical outcomes. Ustekinumab was well-tolerated through 3 years, with no new safety signals 
observed.  
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FIGURE LEGENDS 
Figure 1. Study design and patient flow for IM-UNITI LTE 
 
Figure 2. Patients in clinical remission over time through Week 152 among (A) all randomized 
patients from baseline of IM-UNITI and (B) randomized TNF-naïve patients from baseline of 
IM-UNITI  
 
Figure 3. Patients in clinical remission over time by induction (UNITI-1 or UNITI-2) study 
among randomized patients who entered the long-term extension 
 
Figure 4. Kaplan-Meier curve for the time to loss of response from Week 44 through Week 152 
for randomized patients who were responders to ustekinumab at Week 44, had never been dose 
adjusted, and entered into the long-term extension  
 
Figure 5. Patients in clinical remission over time through Week 152 among all patients who 
entered the long-term extension 
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TABLES  
 
Table 1. Summary of CDAI, CRP, IBDQ values and clinical remission status at Week 44 of 
maintenance among randomized patients (A) and all patients (B) who entered the LTE  
 
Randomized patients 
 Placebo Ustekinumab 
90 mg q12w 
Ustekinumab 
90mg q8w 
Dose adjusters
a 
N 61 84 82 71 
Median CDAI 96.0 95.5 70.5 130.0 
Median IBDQ 180.5 189.0 185.5 171.0 
Median CRP 6.7 3.5 3.7 4.0 
Patients in clinical remission 77.0% 77.4% 84.1% 63.4% 
All patients who entered the LTE 
 Placebo Ustekinumab 
90 mg q12w 
Ustekinumab 
90mg q8w
b 
Combined ustekinumab 
N 151 213 354 567 
Median CDAI 97.0 109.0 111.0 110.0 
Median IBDQ 179.0 179.0 174.0 175.0 
Median CRP 6.0 4.4 3.7 3.8 
Patients in clinical remission 72.2% 68.5% 68.9% 68.8% 
a Dose-adjusters were receiving subcutaneous ustekinumab 90 mg q8w b- Dose-adjusters are included in the ustekinumab 90mg 
q8w group 
CDAI, Crohn’s Disease Activity Index; CRP, c-reactive protein; IBDQ, Inflammatory Bowel Disease Questionnaire; LTE, long-
term extension; q12w, every 12 weeks; q8w, every 8 weeks 
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Table 2. Number of patients who discontinued study agent through week 156
a 
 
 
Placebo Ustekinumab 
90mg q12w 
Ustekinumab 
90mg q8w 
Dose adjusters
b 
N 61 84 82 71 
Patients who discontinued N (%) 57 (93.4%) 23 (27.4%) 18 (22.0%) 24 (33.8%) 
Reason for discontinuation    
Adverse events 11.5% 6.0% 8.5% 12.7% 
Lack of efficacy 8.2% 6.0% 2.4% 8.5% 
Protocol violation 0 0 0 0 
Study terminated by sponsor 0 0 0 0 
Physician decision 0 1.2% 2.4% 1.4% 
Lost to follow-up 1.6% 1.2% 1.2% 0 
Withdraw of consent 6.6% 11.9% 7.3% 8.5% 
Death 0 1.2% 0 2.8% 
Placebo patients discontinued 
due to unblinding 
65.6% 0 0 0 
aRandomized patients who entered the LTE 
bDose-adjusters were receiving subcutaneous ustekinumab 90 mg q8w q12w; every 12 weeks; q8w, every 8 weeks 
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Table 3. IM-UNITI Efficacy Assessments at Week 152 Among Randomized Patients who 
entered LTE
a
 
 
Ustekinumab 
  
90mg SC q8w 
All ustekinumab 
 90 mg SC q12w 90mgSC q8w Prior dose 
adjustment 
Combined  
N 84 82 71 153 237 
Clinical remission N (%) 52 (61.9%) 57 (69.5%) 34 (47.9%) 91 (59.5%) 143 (60.3%) 
Clinical response N (%) 57 (67.9%) 63 (76.8%) 43 (60.6%) 106 (69.3%) 163 (68.8%) 
Clinical remission at Week 
152 and not receiving 
corticosteroids at week 152      
N (%) 
46 (54.8%) 50 (61.0%) 28 (39.4%) 78 (51.0%) 124 (52.3%) 
Clinical remission in UNITI-1 
subset N  
 
32 27 32 59  
N (%) 14 (43.8%) 16 (59.3%) 14 (43.8%) 30 (50.8%)  
Clinical remission in the 
UNITI-2 subset N  
 
52 55 39 94  
N (%) 
 
38 (73.1%) 41 (74.5%) 20 (51.3%) 61 (64.9%)  
Median change from 
maintenance baseline CDAI  
-39.5 -38.5 -15.0 -30.0 -35.0 
aPatients who had insufficient data at the designated analysis time point are considered not to be in clinical remission or response 
CDAI: Crohn’s disease activity index; LTE: long-term extension; Pts: patients; q12w: every 12 weeks; q8w: every 8 weeks;  
SC: subcutaneous. 
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Table 4. Summary of key safety findings per 100 patient-years of follow-up from Week 0 through Week 156; all patients entering 
LTE
  
 
 Placebo Ustekinumab 90mg q12w Ustekinumab 90mg q8w Combined 
ustekinumab 
N 151 213 354 567 
Average duration of follow-up 
(weeks) 
104.0 142.9 140.9 141.7 
Total patient-years of follow-up 301.9 585.4 959.4 1544.8 
Deaths 0 2 4 6 
Number of specified events per hundred patient-years of follow-up (95% CI)   
Adverse events 444.17 
(420.71, 468.59) 
362.00  
(346.75, 377.75) 
406.60  
(393.94, 419.56) 
389.70 
(379.92, 399.67) 
Serious adverse events 19.54  
(14.88, 25.21) 
19.30  
(15.91, 23.21) 
18.76  
(16.12, 21.71) 
18.97 
(16.86, 21.27) 
Infections 100.36  
(89.38, 112.32) 
106.43  
(98.24, 115.13) 
108.29  
(101.81, 115.08) 
107.59 
(102.48, 112.89) 
Serious infections 3.97  
(2.05, 6.94) 
5.98  
(4.16, 8.32) 
3.13  
(2.11, 4.46) 
4.21 
(3.25, 5.36) 
 
CI, confidence interval; LTE, long-term extension; q8w, every 8 weeks; q12w, every 12 weeks;  
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Table 5. Summary of antibody to ustekinumab status in randomized patients during IM-UNITI through Week 156  
 ustekinumab  
 90 mg SC q8w   
 placebo SC
a
  90 mg SC q12w
a
  90 mg SC q8w  
prior dose 
adjustment
b
  combined  all ustekinumab  
N
c 
61 84 82 71 153 237 
       
Antibody status N (%)       
Positive for antibodies to ustekinumab 
at any time through Week 156
d,e
 5 (8.2%) 4 (4.8%) 2 (2.4%) 5 (7.0%) 7 (4.6%) 11 (4.6%) 
       
Negative for antibodies to ustekinumab 
through Week 156
d,f
 56 (91.8%) 80 (95.2%) 80 (97.6%) 66 (93.0%) 146 (95.4%) 226 (95.4%) 
 a Patients who were in clinical response to ustekinumab intravenous induction dosing, were randomized to receive study drugs on entry into the maintenance study, and did 
not meet loss of response criteria from Week 8 through Week 32. 
 b Patients who were in clinical response to ustekinumab induction dosing, were randomized, met loss of clinical response criteria from Week 8 through Week 32, and 
initiated ustekinumab 90 mg SC q8w (for patients randomized to receive placebo SC or ustekinumab 90 mg SC q12w on entry into the maintenance study) or continue 
ustekinumab 90 mg SC q8w (for patients randomized to receive ustekinumab 90 mg SC q8w on entry into the maintenance study) in this maintenance study. 
 c Patients with appropriate samples had 1 or more samples obtained after their first study agent administration of maintenance study. 
 d Denominator is patients with appropriate samples. 
 e Includes all patients who had at least 1 positive sample at any time in this maintenance study. 
 f Excludes patients who were positive at any time through Week 156 in this maintenance study and includes patients whose samples may contain ustekinumab. 
q12w, every 12 weeks; q8w, every 8 weeks; SC, subcutaneous  
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Table 6. Summary of antibody to ustekinumab status through Week 156 by dose adjustment status prior to Week 44; Patients who 
were randomized and entered into LTE 
 Ustekinumab 
 90 mg SC q8w 
  On 90 mg SC q8w due to dose adjustment prior to week 44 
 Placebo SC
a
 90 mg SC 
q12w 
90 mg SC 
q8w 
90 mg SC 
q8w→90 
mg SC q8w 
placebo SC → 
90 mg SC q8w 
90 mg SC q12w → 
90 mg SC q8w 
All 90 mg 
SC q8w 
All 
ustekinumab 
Nb 61 84 82 17 35 19 153 237 
Antibody status         
Positive for antibodies 
to ustekinumab at any 
time through Week 156
,c 
5 (8.2%) 4 (4.8%) 2 (2.4%) 1 (5.9%) 3 (8.6%) 1 (5.3%) 7 (4.6%) 11 (4.6%) 
Negative for antibodies 
to ustekinumab through 
Week 156
c,e
 
56 (91.8%) 80 (95.2%) 80 (97.6%) 16 (94.1%) 32 (91.4%) 18 (94.7%) 146 (95.4%) 226 (95.4%) 
a Patients who were in clinical response to ustekinumab IV induction dosing, were randomized to receive study drugs on entry into the maintenance study, and did not meet loss of 
response criteria from Week 8 through Week 32. 
 b Patients with appropriate samples had 1 or more samples obtained after their first study agent administration of this maintenance study. 
c Denominator is patients with appropriate samples. 
d Includes all patients who had at least 1 positive sample at any time in this maintenance study. 
e Excludes patients who were positive at any time through Week 156 in this maintenance study and includes patients whose samples may contain ustekinumab. 
LTE, long-term extension; SC, subcutaneous; q12w, every 12 weeks, q8w, every 8 weeks 
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FIGURES  
 
Figure 1. 
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Figure 2 
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Figure 3. 
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Figure 4.  
 
CDAI, Crohn’s disease Activity Index; q12w, every 12 weeks; q8w, every 8 weeks; SC ,subcutaneous 
Note: 
Ustekinumab 90 mg SC q12w: Patients who were in clinical response to ustekinumab IV induction dosing, were randomized to 
receive ustekinumab 90 mg SC q12w on entry into the maintenance study, and did not meet loss of response criteria from Week 8 
through Week 32, and were responders at Week 44. 
Ustekinumab 90 mg SC q8w: Patients who were in clinical response to ustekinumab IV induction dosing, were randomized to 
receive ustekinumab 90 mg SC q8w on entry into the maintenance study, and did not meet loss of response criteria from Week 8 
through Week 32, and were responders at Week 44. 
Time to loss of response (Weeks) are calculated from Week 44 to the date of first loss of response (based on observed CDAI 
assessment date), or the first treatment failure date, whichever earlier. Patients who did not lose response prior to or at Week 152 
are censored at the last CDAI assessment date. 
Treatment failure is defined as: Patients received a prohibited Crohn's disease-related surgery, or discontinued study agent due to 
lack of efficacy or due to an adverse event indicated to be of worsening Crohn's disease after week 44. 
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Figure 5.  
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